Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Neovasc to Announce First Quarter 2019 Financial Results on Thursday, May 9th

Neovasc to Announce First Quarter 2019 Financial Results on Thursday, May 9th

Canada NewsWire

Conference Call Scheduled for 4:30 pm Eastern Time on May 9th 

NASDAQ, TSX: NVCN

VANCOUVER, May 3, 2019 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it will report financial results for the quarter ended March 31, 2019 and host a conference call and webcast at 4:30 pm Eastern Time on Thursday, May 9, 2019.

 

Conference Call & Webcast
Thursday, May 9th @ 4:30 pm Eastern Time

Domestic:

877-407-9208

International:

201-493-6784

Passcode:

13689510

Webcast:

http://public.viavid.com/index.php?id=133943  

 

A replay of the event will be available via webcast through August 9st on the Company's website, www.neovasc.com, or at http://public.viavid.com/index.php?id=133943.

About Neovasc Inc. 
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe. For more information, visit: www.neovasc.com.

 

Cision View original content:http://www.prnewswire.com/news-releases/neovasc-to-announce-first-quarter-2019-financial-results-on-thursday-may-9th-300843366.html

SOURCE Neovasc Inc.

View original content: http://www.newswire.ca/en/releases/archive/May2019/03/c4573.html

Chris Clark, Chief Financial Officer, Neovasc Inc., 604 248-4138, cclark@neovasc.com; Jeremy Feffer, LifeSci Advisors, LLC, 212-915-2568Copyright CNW Group 2019